SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥146.69+CN¥3.80 (+2.66%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.62% below the high.
Loading market information…
HKSE · 2511.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 02:32 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
HighTide Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 34.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
HighTide Therapeutics Inc’s next earnings report is currently expected on Mar 26, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow HighTide Therapeutics Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥146.69+CN¥3.80 (+2.66%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.62% below the high.
CN¥49.14+CN¥0.52 (+1.07%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.03% below the high.
HK$51.75+HK$1.10 (+2.17%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.64% below the high.
HK$43.00HK$0.00 (0.0%)
Suzhou Ribo Life Science Co’s quoted price sits in the lower half of its reported 52-week range, 55.11% below the high.
HK$5.16-HK$0.06 (-1.15%)
Ascletis Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.04% below the high.
HK$8.85+HK$0.19 (+2.2%)
TransThera Sciences (Nanjing). Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.4% below the high.
HK$2.25-HK$0.02 (-0.66%)
Hua Medicine (Shanghai) Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.02% below the high.
HK$4.79+HK$0.96 (+25.07%)
PegBio Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 93.78% below the high.
